Exosomes 100bn

Description

MSC-derived exosomes represent a next-generation approach in regenerative medicine, utilising cell-free biological signalling to support tissue repair, inflammation modulation, and cellular communication. These nano-sized extracellular vesicles contain a complex profile of growth factors, cytokines, lipids, and genetic material that influence key regenerative pathways.

Unlike stem cell therapies, exosomes function through paracrine signalling, delivering bioactive molecules that help regulate cellular processes such as angiogenesis, immune response, and tissue remodelling. This makes them particularly relevant in protocols targeting recovery, inflammation, and overall cellular optimisation.

As outlined in the clinical guidance, exosomes are administered via intravenous infusion following appropriate dilution (typically with saline), allowing for systemic distribution and controlled delivery over a monitored infusion period.

Quality and safety are supported through rigorous testing, including sterility, endotoxin, and mycoplasma assessments, ensuring absence of contamination and consistency of the final product.

Exosome-based therapies are currently utilised in advanced clinical and research settings exploring applications in musculoskeletal recovery, immune modulation, and longevity-focused interventions.

Key Clinical Benefits:

• Supports cellular communication and regenerative signalling pathways
• Promotes tissue repair and recovery processes
• Contributes to modulation of inflammation and immune response
• Supports angiogenesis and microvascular function
• Aids cellular repair and structural regeneration
• Supports musculoskeletal recovery and tissue resilience
• Contributes to overall cellular optimisation and longevity pathways
• Enables systemic delivery of bioactive growth factors and signalling molecules